Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: A meta-analysis of individual patient data from global clinical registration studies in 1678 participants

 The writing of the manuscript and associated statistical analyses were funded by Allergan. All studies reported herein were funded by the sponsoring pharmaceutical companies: Allergan, GlaxoSmithKline Japan, and GlaxoSmithKline China.

 Disclosure: Dr Brin, Mr Boodhoo, Ms James, Dr Demos, Dr Terashima, Ms Gu, and Ms Bowen are employed by the pharmaceutical companies and receive direct salary compensation. Dr Brin, Ms Eadie, Ms Bowen, Mr Boodhoo, Dr Demos, and Ms James also hold an equity interest in the companies in the form of stock, stock options, or both. Dr Pogoda and Ms Eadie have consulting contracts with Allergan. None of the authors have any commercial associations with any company that makes a competing product. No ghost writers or other third parties were involved in the preparation of the manuscript.

PII: S0190-9622(09)00725-7

doi:10.1016/j.jaad.2009.06.040

© 2009 American Academy of Dermatology, Inc. Published by Elsevier Inc All rights reserved.